Brigatinib

Evidence Level: L5

Predicted Indications: 9

Brigatinib

Pharmacist Assessment Report

Brigatinib: ALK/multi-kinase inhibitor → fibromatosis, gingival

One-Sentence Summary

Brigatinib is an oral kinase inhibitor that targets ALK and several other tyrosine kinases and is marketed in Canada as ALUNBRIG. The TxGNN model predicts it may be relevant to gingival fibromatosis, with a score of 0.9989. There are no clinical trials and no publications for this disease, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Gingival fibromatosis (fibromatosis, gingival)
TxGNN Prediction Score	0.9989
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Brigatinib is known from the literature as a next-generation ALK inhibitor that also inhibits other tyrosine kinases, such as ROS1 and EGFR.

No mechanistic link between this kinase inhibition and gingival fibromatosis has been identified. The high TxGNN score is a model-based prediction only. Gingival fibromatosis is a non-malignant overgrowth of gum tissue, and no biological rationale supports using a systemic oncology kinase inhibitor for it. The similarity between the drug’s current use and this condition has not been assessed.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02479214	ALUNBRIG	Not recorded	Not recorded
02479206	ALUNBRIG	Not recorded	Not recorded
02479222	ALUNBRIG	Not recorded	Not recorded
02479230	ALUNBRIG	Not recorded	Not recorded

All four single-ingredient licences are valid.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screen returned 100 records. Major-level interactions among those listed include aprepitant, dexamethasone and clarithromycin. Many moderate-level interactions are also listed, including acid-reducing agents (famotidine, ranitidine, rabeprazole, cimetidine) and several antidiabetic drugs (metformin, pioglitazone, alogliptin, canagliflozin, dapagliflozin).

Warnings and contraindications from the package insert were not available. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no clinical trials, no publications and no identified mechanistic link, so it remains a model output only (evidence level L5). Systemic kinase inhibitor toxicity would be hard to justify for a benign gum condition without supporting data.

To proceed, the following is needed:

A mechanistic rationale linking brigatinib’s kinase targets to gingival fibromatosis
Preclinical or clinical studies in this disease
Package insert warnings and contraindications from Health Canada
Detailed mechanism-of-action data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.